{
    "clinical_study": {
        "@rank": "8347", 
        "arm_group": [
            {
                "arm_group_label": "Ketorolac + Ranibizumab", 
                "arm_group_type": "Experimental", 
                "description": "3 monthly ranibizumab, then as needed plus ketorolac eyedrops TID"
            }, 
            {
                "arm_group_label": "Ranibizumab Alone", 
                "arm_group_type": "Active Comparator", 
                "description": "3 monthly ranibizumab, then as needed"
            }
        ], 
        "brief_summary": {
            "textblock": "The addition of an anti-inflammatory agent could be a valid option for controlling choroidal\n      neovascularization, as simply inhibiting VEGF addresses neither the multifactorial\n      pathogenesis of choroidal neovascularization nor the underlying cause of VEGF production."
        }, 
        "brief_title": "Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Wet Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Wet Macular Degeneration"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. ability to provide written informed consent and comply with study assessments for the\n             full duration of the study;\n\n          2. age >40 years;\n\n          3. presence of treatment-na\u00efve neovascular AMD with a visual acuity between 20/25 and\n             20/200 on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Inclusion\n             criteria for AMD were neovascularisation, fluid, or haemorrhage under the fovea.\n\n        Exclusion Criteria:\n\n          1. any previous intravitreal treatment;\n\n          2. previous laser treatment in the study eye;\n\n          3. myopia >7 dioptres in the study eye;\n\n          4. concurrent eye disease in the study eye that could compromise visual acuity (eg,\n             diabetic retinopathy, advanced glaucoma);\n\n          5. concurrent corneal epithelial disruption or any condition that would affect the\n             ability of the cornea to heal;\n\n          6. known sensitivity to any component of the formulations under investigation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02060604", 
            "org_study_id": "NSAIDs_01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ketorolac + Ranibizumab", 
                "description": "3 monthly ranibizumab, then as needed Ketorolac TID", 
                "intervention_name": "Ketorolac + Ranibizumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ranibizumab Alone", 
                "description": "3 monthly ranibizumab, then as needed", 
                "intervention_name": "Ranibizumab", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Ketorolac", 
                "Ketorolac Tromethamine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ketorolac", 
            "NSAIDs", 
            "wet macular degeneration", 
            "choroidal neovascularization"
        ], 
        "lastchanged_date": "February 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Brescia", 
                    "country": "Italy", 
                    "state": "BS", 
                    "zip": "25123"
                }, 
                "name": "Spedali Civili di Brescia"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration", 
        "overall_official": [
            {
                "affiliation": "University of Brescia, Italy", 
                "last_name": "Andrea Russo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Brescia, Italy", 
                "last_name": "Luisa Delcassi, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Brescia, Italy", 
                "last_name": "Francesco Semeraro, Professor", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Sistema Sanitario Nazionale"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "mean change in study eye visual acuity as measured by the best-corrected ETDRS letter score", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02060604"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e0 degli Studi di Brescia", 
            "investigator_full_name": "Andrea Russo", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "mean change in central macular thickness", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "mean number of intravitreal injections over the 12-month period", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "adverse ocular events at 12 months", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Universit\u00e0 degli Studi di Brescia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universit\u00e0 degli Studi di Brescia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}